Physicians for Responsible Opioid Prescribing (PROP) has appointed Dr. Andrew Kolodny to succeed Dr. Jane Ballantyne as the organization’s next president. The appointment will become effective June 21, 2022. Read the full press release here.
Industry-funded medical education is always promotion
Industry-funded CME has been used – and is still used – to promote opioids and many other drugs. In an article in the BMJ, PROP Executive Council member Adriane Fugh-Berman exposes how industry-funded CME uses CME to promote unproven or disproven […]
Making controlled drugs more available will not target the problem
In a commentary piece for the Journal of Studies on Alcohol and Drugs, PROP leader Anna Lembke discusses how the expanded use of controlled substances should not be labeled “safe” without guarding against misuse, addiction, diversion and death. Unsafe Supply […]
PROP leader studies dental opioid prescription trends
In a recent retrospective study, researchers including PROP leader Dr. David Juurlink found that 4.4% of patients prescribed opioids by a dentist following common dental procedures developed persistent use. Nearly 1% of these patients had evidence of an overdose within […]
PROP Leaders discuss chronic opioid use and social rejection
Mark Sullivan and Jane Ballantyne publish study in Annals of Family Medicine on physical and social pain of patients on long-term opioid therapy.
PROP’s Andrew Kolodny comments for the New Yorker on the role Purdue Pharma and the Sacklers played in causing the opioid crisis.
- 1
- 2
- 3
- …
- 5
- Next Page »
Follow us on Twitter